Clarimicina Dosage

Was this medicine useful for you?
sponsored

Dosage of Clarimicina in details

The dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.
sponsored

Important Administration Instructions

Clarimicina tablets, USP and Clarimicina for oral suspension, USP may be given with or without food.

Clarimicina extended-release tablets, USP should be taken with food. Swallow Clarimicina extended-release tablets whole; do not chew, break or crush Clarimicina extended-release tablets.

Adult Dosage

The recommended dosages of Clarimicina tablets, USP and Clarimicina extended-release tablets, USP for the treatment of mild to moderate infections in adults are listed in Table 1.

Table 1. Adult Dosage Guidelines

Clarimicina Tablets

Clarimicina Extended-Release Tablets

Infection

Dosage

(every 12 hours)

Duration

(days)

Dosage

(every 24 hours)

Duration

(days)

Acute bacterial exacerbation of chronic bronchitis

250 - 500 mga

7b - 14

1 gram

7

Acute maxillary sinusitis

500 mg

14

1 gram

14

Community-acquired pneumonia

250 mgc

7d - 14

1 gramc

7

Pharyngitis/Tonsillitis

250 mg

10

-

-

Uncomplicated skin and skin structure infections

250 mg

7 - 14

-

-

Treatment and prophylaxis of disseminated Mycobacterium avium disease

500 mge

-

-

-

H.pylori eradication to reduce the risk of duodenal ulcer recurrence with amoxicillin and omeprazole or lansoprazole

500 mg

10 - 14

-

-

H.pylori eradication to reduce the risk of duodenal ulcer recurrence with omeprazole

500 mg every

8 hours

14

-

-

a For M. catarrhalis and S. pneumoniae use 250 mg. For H. influenzae and H. parainfluenzae, use 500 mg.

bFor H parainfluenzae, the duration of therapy is 7 days.

cFor H. parainfluenzae and M. catarrhalis use Clarimicina extended-release tablets only.

dFor H. influenzae, the duration of therapy is 7 days.

e Clarimicina therapy should continue if clinical response is observed. Clarimicina can be discontinued when the patient is considered at low risk of disseminated infection.

Combination Dosing Regimens for H. pylori Infection

The recommended adult dosage is 500 mg Clarimicina tablets given every 8 hours and 40 mg omeprazole given once every morning for 14 days. An additional 14 days of omeprazole 20 mg once daily is recommended for ulcer healing and symptom relief.

Pediatric Dosage

The recommended daily dosage is 15 mg/kg/day divided every 12 hours for 10 days (up to the adult dose). Refer to dosage regimens for mycobacterial infections in pediatric patients for additional dosage information.

Dosage Regimens for Mycobacterial Infections

For the treatment of disseminated infection due to Mycobacterium avium complex (MAC), Clarimicina tablets and Clarimicina for oral suspension are recommended as the primary agents. Clarimicina tablets and Clarimicina oral suspension should be used in combination with other antimycobacterial drugs (e.g. ethambutol) that have shown in vitro activity against MAC or clinical benefit in MAC treatment.

Adult Patients

For treatment and prophylaxis of mycobacterial infections in adults, the recommended dose of Clarimicina is 500 mg every 12 hours.

Pediatric Patients

For treatment and prophylaxis of mycobacterial infections in pediatric patients, the recommended dose is 7.5 mg/kg every 12 hours up to 500 mg every 12 hours..

Clarimicina therapy should continue if clinical response is observed. Clarimicina can be discontinued when the patient is considered at low risk of disseminated infection.

Dosage Adjustment in Patients with Renal Impairment

Table 2. Clarimicina Dosage Adjustments in Patients with Renal Impairment

Recommended Clarimicina Dosage Reduction

Patients with severe renal impairment (CLcr of <30 mL/min)

Reduce the dosage of Clarimicina by 50%

Patients with moderate renal impairment (CLcr of 30 to 60 mL/min) taking concomitant atazanavir or ritonavir-containing regimens

Reduce the dosage of Clarimicina by 50%

Patients with severe renal impairment (CLcr of <30 mL/min) taking concomitant atazanavir or ritonavir-containing regimens

Reduce the dosage of Clarimicina by 75%

Dosage Adjustment Due to Drug Interactions

Decrease the dose of Clarimicina by 50% when coadministered with atazanavir. Dosage adjustments for other drugs when coadministered with Clarimicina may be recommended due to drug interactions.

Reconstitution of Clarimicina for

Oral Suspension

The supplied Clarimicina for oral suspension must be reconstituted with water prior to administration of Clarimicina for oral suspension. Table 3 below indicates the volume of water to be added when reconstituting. To reconstitute:

a. Add half the volume of water to the bottle containing the Clarimicina for oral suspension and shake vigorously.

b. Add the remainder of water to the bottle and shake.

Shake well before each use. After mixing, store at 15° to 30°C (59° to 86°F) and use within 14 days. Do not refrigerate.

Table 3. Volume of Water to be Added When Reconstituting Clarimicina for

Oral Suspension

Total Volume After Reconstitution

Clarimicina Concentration AfterReconstitution

Amount of Water to be Added

50 mL

125 mg/5 mL

27 mL

100 mL

125 mg/5 mL

55 mL

50 mL

250 mg/5 mL

27 mL

100 mL

250 mg/5 mL

55 mL

What other drugs will affect Clarimicina?

Many drugs can interact with Clarimicina. Not all possible interactions are listed here. Tell your doctor about all your medications and any you start or stop using during treatment with Clarimicina, especially:

This list is not complete and many other drugs can interact with Clarimicina. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Give a list of all your medicines to any healthcare provider who treats you.

Clarimicina interactions

Interactions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Clarimicina, it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.
sponsored

Clarimicina: Data available to date indicate that Clarimicina is metabolized primarily by the hepatic cytochrome P-450 3A (CYP3A) isozyme. This is an important mechanism determining many drug interactions.

The metabolism of other drugs by this system may be inhibited by concomitant administration with Clarimicina and may be associated with elevations in serum levels of drug classes known or suspected to be metabolized by the same CYP450 and CYP3A isozyme.

Other Drug Interactions: Elevated digoxin serum concentrations have been reported in patients receiving Clarimicina tablets and digoxin concomitantly. Monitoring of serum digoxin levels should be considered.

There have been post-marketing reports of Torsades de pointes occurring with concurrent use of Clarimicina and quinidine or disopyramide. Serum levels of these medications should be monitored during Clarimicina therapy.

Rhabdomyolysis coincident with the co-administration of Clarimicina and the HMG-CoA reductase inhibitors eg, lovastatin and simvastatin has rarely been reported.

Antiretroviral Drug Interactions: Simultaneous oral administration of Clarimicina tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. Because Clarimicina appears to interfere with the absorption of simultaneously administered oral zidovudine, this interaction can be largely avoided by staggering the doses of Clarimicina and zidovudine. This interaction does not appear to occur in pediatric HIV-infected patients taking Clarimicina suspension with zidovudine or dideoxyinosine.

A pharmacokinetic study demonstrated that the concomitant administration of ritonavir 200 mg every 8 hrs and Clarimicina 500 mg every 12 hrs resulted in a marked inhibition of the metabolism of Clarimicina.

For patients with renal impairment, the following dosage adjustments should be considered: For patients with CrCl 30-60 mL/min, the dose of Clarimicina should be reduced by 50%. For patients with CrCl <30 mL, the dose of Clarimicina should be decreased by 75%. Doses of Clarimicina >1 g/day should not be co-administered with ritonavir.

Clarimicina OD: As with other macrolide antibiotics, the use of Clarimicina in patients concurrently taking drugs metabolized by the cytochrome P-450 system (eg, cilostazol, methylprednisolone, anticoagulants eg, warfarin, quinidine, sildenafil, ergot alkaloids, alprazolam, triazolam, midazolam, disopyramide, lovastatin, rifabutin, phenytoin, cyclosporin, vinblastine, valproate and tacrolimus) may be associated with elevations in serum levels of these other drugs.

Digoxin: Elevated digoxin serum concentrations have been reported in patients receiving Clarimicina tablets and digoxin concomitantly. Monitoring of serum digoxin levels should be considered.

Quinidine/Disopyramide: There have been post-marketed reports of Torsades de pointes occurring with concurrent use of Clarimicina and quinidine or disopyramide. Electrocardiogram and serum levels of these medications should be monitored during Clarimicina therapy.

HMG-CoA Reductase Inhibitors: As with other macrolides, Clarimicina has been reported to increase concentrations of HMG-CoA reductase inhibitors (eg, statins). Rhabdomyolysis has also been reported in patients taking these drugs concomitantly.

Theophylline, Carbamazepine: The administration of Clarimicina to patients receiving theophylline or carbamazepine has been associated with an increase in serum theophylline or carbamazepine levels.

Oral Anticoagulants:

Concomitant administration of Clarimicina and oral anticoagulants may potentiate the effects of oral anticoagulants. Prothrombin time should be carefully monitored while patients are receiving Clarimicina and oral anticoagulants simultaneously.

Ritonavir: Ritonavir increases AUC, Cmax and Cmin of Clarimicina when administered concurrently. Because of the large therapeutic window for Clarimicina, no dosage reduction should be necessary in patients with normal renal function. However, for patients with renal impairment, the following dosage adjustments should be considered: For patients with CrCl 30-60 mL/min, the dose of Clarimicina should be reduced by 50%. For patients with CrCl <30 mL/min, the dose of Clarimicina should be decreased by 75%. Doses of Clarimicina >1 g/day should not be co-administered with ritonavir.

Efavirenz, Nevirapine, Rifampicin and Rifabutin: Strong inducers of the cytochrome P-450 metabolism system eg, efavirenz, nevirapine, rifampicin and rifabutin may accelerate the metabolism of Clarimicina and thus, lower the plasma levels of Clarimicina. Since the microbiological activities of Clarimicina and 14-OH-Clarimicina are different for different bacteria, the intended therapeutic effect could be impaired during concomitant administration of Clarimicina and enzyme inducers.

Sildenafil, Tadalafil and Vardenafil: Each of these phosphodiesterase inhibitors is metabolized, at least in part, by CYP3A, and CYP3A may be inhibited by concomitantly administered Clarimicina. Reduction in sildenafil, tadalafil and vardenafil dosages should be considered when these drugs are co-administered with Clarimicina.

Triazolam: Drug interactions and CNS effects (eg, somnolence and confusion) with the concomitant use of Clarimicina and triazolam have been reported. Monitoring the patient for increased CNS pharmacological effects is suggested.

Colchicine: When Clarimicina and colchicine are administered together, inhibition of Pgp and/or CYP3A by Clarimicina may lead to increased exposure to colchicine. Patients should be monitored for clinical symptoms of colchicine toxicity.

Itraconazole: Both Clarimicina and itraconazole are substrates and inhibitors of CYP3A. Clarimicina may increase the plasma levels of itraconazole, while itraconazole may increase the plasma levels of Clarimicina. Patients taking itraconazole and Clarimicina concomitantly should be monitored closely for signs and symptoms of increased or prolonged pharmacological effect.

Zidovudine: Simultaneous oral administration of Clarimicina tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. This interaction does not appear to occur in pediatric HIV-infected patients taking Clarimicina suspension with zidovudine or dideoxyinosine.


sponsored

References

  1. DailyMed. "CLARITHROMYCIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. FDA/SPL Indexing Data. "H1250JIK0A: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
  3. MeSH. "Cytochrome P-450 CYP3A Inhibitors". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Clarimicina are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Clarimicina. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported frequency of use

No survey data has been collected yet


Consumer reported doses

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 27 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2022 ndrugs.com All Rights Reserved